Analyst Ratings January 23, 2026

RBC Capital Elevates Price Target for Texas Capital Bancshares to $110 Amid Continued Strong Performance

Analyst Ratings Reflect Confidence in Texas Capital Bancshares’ Growth and Financial Results Despite Seasonal Challenges

By Nina Shah TCBI
RBC Capital Elevates Price Target for Texas Capital Bancshares to $110 Amid Continued Strong Performance
TCBI

RBC Capital has increased its price target for Texas Capital Bancshares to $110 from $105 while keeping a Sector Perform rating. The increment follows the company’s solid quarterly performance, robust loan growth, and better-than-expected earnings and revenue in Q4 2025. The stock trades near its 52-week high, supported by significant returns over the past year and positive momentum across product lines.

Key Points

  • RBC Capital raised Texas Capital Bancshares’ price target to $110, indicating a 7.6% potential gain from current prices.
  • The company demonstrated strong commercial and industrial loan growth alongside an expanding mortgage warehouse business, contributing to overall franchise momentum.
  • Texas Capital Bancshares delivered better-than-expected earnings and revenue in Q4 2025, reflecting enhanced margin and expense trends.

RBC Capital recently raised its price target for Texas Capital Bancshares (NASDAQ:TCBI) to $110 from a previous $105, though it maintained a Sector Perform rating on the stock. This revised valuation implies a 7.6% upside over the current share price, which stands at $102.24. Notably, TCBI is trading close to its 52-week peak of $105.36.

The price target adjustment reflects RBC Capital’s evaluation of what it terms "another solid quarter" for Texas Capital Bancshares, despite facing some anticipated seasonal headwinds. Over the past twelve months, the stock has delivered a substantial total return of 32.87%, underscoring its strong market performance.

Examining the company’s operational dynamics, RBC Capital highlighted Texas Capital Bancshares’ growth in commercial and industrial (C&I) lending alongside expansion in its mortgage warehouse operations. These sectors contributed positively to the bank's momentum during the quarter.

In addition, the bank posted a margin that surpassed expectations, supported by favorable underlying trends in fees and expenses. This financial discipline and revenue diversification indicate improving quality across the franchise.

RBC Capital’s assessment noted broad-based gains across multiple product lines, prompting forward-looking adjustments to its financial estimates for the firm. The sustained momentum suggests ongoing strength in Texas Capital Bancshares’ portfolio despite broader economic variabilities.

Furthermore, recent disclosure by Texas Capital Bancshares for the fourth quarter of 2025 revealed impressive financial outcomes exceeding market forecasts. Earnings per share reached $2.08, outperforming the expected $1.76 by 18.18%, reflecting a significant earnings surprise. Total revenue also surpassed projections, coming in at $327.48 million compared to an anticipated $323.29 million.

This set of financial results indicates a solid quarter for Texas Capital Bancshares and offers encouraging signals for investors assessing the company’s recent performance trajectory. Strong earnings and resilient top-line figures are crucial metrics that can influence shareholder confidence and valuation assessments.

The stock’s robust performance and favorable earnings announcements underline the bank’s ability to navigate seasonal challenges while sustaining growth in core lending and fee-generating segments.

Risks

  • Anticipated seasonal headwinds could pose challenges to quarterly performance consistency for Texas Capital Bancshares.
  • Potential fluctuations in fee and expense trends may impact future margin stability across the bank’s diverse product mix.
  • Adjustments to analyst estimates highlight some uncertainty regarding forward-looking projections amid evolving market conditions.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026